S
Septerna
Biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs)
About Septerna
Septerna is a pioneering startup in the biotechnology sector, focusing on the development of G protein-coupled receptors (GPCRs) drug discovery. GPCRs are proteins that play a crucial role in regulating human physiology and are a significant target for pharmaceuticals. However, many potential GPCR targets have been inaccessible to modern drug discovery technologies. Septerna is changing this scenario with its innovative Native Complex™ Platform.
Read full description
The Native Complex™ Platform is a groundbreaking technology that reproduces GPCRs with their original structure, function, and dynamics outside of the cellular environment. This technology allows for the first time, the industrial-scale drug discovery, including structure-based drug design and ultra-large-scale screening for the entire GPCR target class. This opens up new opportunities for previously "undruggable" GPCRs to be used as therapeutic targets.
Septerna's business model is centered around the development and commercialization of this platform. The company's primary clients are likely to be pharmaceutical companies seeking to develop new drugs targeting GPCRs. By offering a solution to a previously unmet need in the pharmaceutical industry, Septerna has positioned itself in a niche market with significant potential for growth.
Septerna generates revenue by licensing its technology to pharmaceutical companies for drug discovery and development. The company also stands to earn from the sale of its proprietary GPCR-targeted medicines.
In summary, Septerna is a game-changer in the biotech industry, leveraging its innovative technology to unlock new therapeutic targets and spearhead a new era of GPCR-targeted medicines.
Latest news
Press, funding announcements and product moves mentioning Septerna.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A15 investors entered at this stage
Third Rock Ventures
Casdin Capital
BVF Partners
Catalio Capital Management
Invus
Samsara BioCapital
Logos Capital
RA Capital Management
Goldman Sachs Asset Management- SCSoleus Capital
Mirae Asset Capital
Driehaus Capital Management
Vertex Ventures HC
Woodline Partners
Deep Track Capital
Series B and later9 investors entered at this stage
- MUMonash University
- RA Capital Management
- DCDeep Track Capital
- Goldman Sachs Asset Management
- DMDriehaus Capital Management
- MCMirae Asset Capital
- VHVertex Ventures HC
- WPWoodline Partners
- SCSoleus Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
16 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Septerna on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Septerna on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.